



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 09/892,485 | 06/28/2001 | Mitsuko Ishihara | 210577US0SRD | 3202 |

22850 7590 05/12/2003

OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA, VA 22314

[REDACTED] EXAMINER

CHAKRABARTI, ARUN K

| ART UNIT | PAPER NUMBER |
|----------|--------------|
| 1634 | |

DATE MAILED: 05/12/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

| | | |
|------------------------------|------------------------------|------------------|
| Office Action Summary | Application No. | Applicant(s) |
| | 09/892,485 | ishihara |
| | Examiner Arun Chakrabarti | Art Unit 1634 |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on Nov 27, 2002.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

4) Claim(s) 29-69 is/are pending in the application.
 4a) Of the above, claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 29-69 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claims _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
 If approved, corrected drawings are required in reply to this Office action.
 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some* c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
 *See the attached detailed Office action for a list of the certified copies not received.
 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
 a) The translation of the foreign language provisional application has been received.
 15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____
 4) Interview Summary (PTO-413) Paper No(s). _____
 5) Notice of Informal Patent Application (PTO-152)
 6) Other: *Detailed Action*

Art Unit: 1634

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on November 27, 2002 has been entered. Previous office action mailed on March 11, 2003, has been withdrawn because it was non-responsive to RCE filed on November 27, 2002.

Specification

2. Claims 1-28 have been canceled. New claims 29-69 have been added.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Art Unit: 1634

4. Claims 38, 54, and 65-66 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claim 38 is rejected over the recitation of the negative limitations “not expressed in (B), c), or (D)” and “not expressed in (A)”, and claims 54, 65 and 66 are rejected over the recitation of the negative limitations “which has not been genetically engineered” (See MPEP 2173.05 (I)) - “Any negative limitation or exclusionary proviso must have basis in the original disclosure. See *Ex parte Grasselli*, USPQ 393 (Bd. App. 1983), *aff'd mem.*, 738 F.2d 453 (Fed. Cir. 1984). The mere absence of a positive recitation is not basis for an exclusion. Any claim containing a negative limitation which does not have basis in the original disclosure should be rejected under 35 U.S.C. 112, first paragraph as failing to comply with the written description requirement”. In the instant application, negative limitations inserted in the amended claims do not have any expressed basis in the original specification.

5. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claims 68-69 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Art Unit: 1634

Claim 68 is rejected over the recitation of the phrase, "gone expression pattern". It is not clear if a new expression pattern (not explained in the specification) is claimed or gene expression pattern is claimed or both are claimed. The metes and bounds of the claim are vague and indefinite.

Claim Rejections - 35 USC § 102

7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

8. Claims 29-33, 46, 53 and 67 are rejected under 35 U.S.C. 102 (e) as being anticipated by Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999).

Lonial et al teach a method of detecting an endocrine disrupting action of a test substance (Abstract), comprising:

a) culturing a cell having a sensitivity to an endocrine hormone in a first culture system in which endocrine hormone and the test substance are present (Claim 12 and column 10, line 65 to column 12, line 16);

b) determining the presence or absence of an endocrine disrupting action of the test substance by comparing a first gene expression pattern obtained from the cell of the first culture system with a second gene expression pattern expressed by a cell having a sensitivity to the endocrine hormone (Claim 12 and column 10, line 65 to column 12, line 16 and Figure 3).

Art Unit: 1634

Lonial et al inherently teach a method comprising a second, third and fourth culture system in which presence and absence of endocrine hormone and test substances are modulated (Claim 12 and column 10, line 65 to column 12, line 16 and Figure 3).

Lonial et al inherently teach a method, wherein the cell is a human cell (Abstract and Cell Culture Section).

Claim Rejections - 35 USC § 103

9. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(a) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

Art Unit: 1634

10. Claims 37, 41, 42, 43, 45 are rejected under 35 U.S.C. 103 (a) over Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999) in view of Gillies et al. (U.S. Patent 4,663,281) (May 5, 1987).

Lonial et al teach a method of claims 29-33, 46, 53 and 67 as described above.

Lonial et al do not teach a method, wherein comparison of the gene expression patterns are made by comparing bands obtained by subjecting a gene group contained in each of gene expression patterns to electrophoretic separation.

Gillies et al teach a method, wherein comparison of the gene expression patterns are made by comparing bands obtained by subjecting a gene group contained in each of gene expression patterns to electrophoretic separation (Figures 2, 7, and 8).

Lonial et al do not teach a method, wherein comparison of the gene expression patterns are made by hybridizing gene groups, and subtracting unhybridized genes.

Gillies et al teach a method, wherein comparison of the gene expression patterns are made by hybridizing gene groups, and subtracting unhybridized genes (Figures 7-8).

Lonial et al do not teach a method, wherein glycoprotein is expressed in cells.

Gillies et al teach a method, wherein glycoprotein is expressed in cells (Column 5, lines 30-37).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute the method, wherein glycoprotein is expressed in cells and wherein comparison of the gene expression patterns are made by comparing bands

Art Unit: 1634

obtained by subjecting a gene group contained in each of gene expression patterns to electrophoretic separation of Gillies et al in the method of Lonial et al, since Gillies et al states, "More specifically, the invention relates to a method of exploiting the genetic mechanism of certain types of eukaryotic cells to produce relatively large quantities of a protein of interest or its precursor (Column 1, lines 11-15)" Moreover, Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the development of a fast and effective in vitro screening system (Column 2, lines 29-31)". By employing scientific reasoning, an ordinary practitioner would have been motivated to combine and substitute the method wherein glycoprotein is expressed in cells and wherein comparison of the gene expression patterns are made by comparing bands obtained by subjecting a gene group contained in each of gene expression patterns to electrophoretic separation of Gillies et al in the method of Lonial et al. in order to improve the process for detecting an endocrine disrupting action of a test substance and in order to achieve the express advantages, as noted by Gillies et al, of an invention which relates to a method of exploiting the genetic mechanism of certain types of eukaryotic cells to produce relatively large quantities of a protein of interest or its precursor and also in order to achieve the express advantages, as noted by Lonial et al, which would facilitate the search for hormone agonists and antagonists by the development of a fast and effective in vitro screening system.

Art Unit: 1634

11. Claims 34, 35, 36, 38, 39, and 40 are rejected under 35 U.S.C. 103 (a) over Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999) in view of Pearson et al. (U.S. Patent 5,916,779) (June 29, 1999).

Lonial et al teach a method of claims 29-33, 46, 53 and 67 as described above.

Lonial et al do not teach a method, wherein RNA is recovered and subjected to RT PCR to detect a band specific to gene expression pattern.

Pearson et al teach a method, wherein RNA is recovered and subjected to RT PCR to detect a band specific to gene expression pattern (Abstract, Claim 1 and Figure 1 and Column 2, lines 13-56).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute the method, wherein RNA is recovered and subjected to RT PCR to detect a band specific to gene expression pattern of Pearson et al in the method of Lonial et al, since Pearson et al states, "Amplification of RNA and DNA targets is often desirable for diagnostic application of amplification technologies, as this gives the greatest number of amplifiable targets per sample. , and as a result, the greatest diagnostic sensitivity. Amplification of RNA targets is also useful for diagnostic monitoring of RNA-related conditions such as certain viremias, up regulation of cancer genes, etc. Amplification of RNA targets is referred to as "reverse transcription amplification", the best known method being reverse transcription PCR.(Column 2, lines 17-26)". Moreover, Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the

Art Unit: 1634

development of a fast and effective in vitro screening system (Column 2, lines 29-31)". By employing scientific reasoning, an ordinary practitioner would have been motivated to combine and substitute the method wherein RNA is recovered and subjected to RT PCR to detect a band specific to gene expression pattern of Pearson et al in the method of Lonial et al. in order to improve the process for detecting an endocrine disrupting action of a test substance and in order to achieve the express advantages, as noted by Pearson et al, of an invention which provides amplification of RNA targets by the best known method reverse transcription PCR useful for diagnostic monitoring of RNA-related conditions such as certain viremias, up regulation of cancer genes, etc. and also in order to achieve the express advantages, as noted by Lonial et al, which would facilitate the search for hormone agonists and antagonists by the development of a fast and effective in vitro screening system.

12. Claim 44 is rejected under 35 U.S.C. 103 (a) over Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999) in view of Schneider et al. (U.S. Patent 6,537,432 B1) (March 25, 2003).

Lonial et al teach a method of claims 29-33, 46, 53 and 67 as described above.

Lonial et al does not teach a method of electrophoretically separating proteins using two-dimensional elecctrophoresis.

Schneider et al. teaches a method of electrophoretically separating proteins using two-dimensional electrophoresis. (Abstract and Claims 1-3, and Example 4).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute a method of electrophoretically separating

Art Unit: 1634

proteins using two-dimensional electrophoresis of Schneider et al in the method of Lonial et al, since Schneider et al states, "The methods can be used in a variety of different applications including, creating proteomic databases, comparative expression studies, diagnostics, structure activity relationships and metabolic engineering investigations (Abstract, last sentence)".

Moreover, Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the development of a fast and effective in vitro screening system (Column 2, lines 29-31)". By employing scientific reasoning, an ordinary practitioner would have been motivated to combine and substitute a method of electrophoretically separating proteins using two-dimensional electrophoresis of Schneider et al in the method of Lonial et al. in order to improve the process for detecting an endocrine disrupting action of a test substance and in order to achieve the express advantages, as noted by Scneider et al, of an invention which can be used in a variety of different applications including, creating proteomic databases, comparative expression studies, diagnostics, structure activity relationships and metabolic engineering investigations, and also in order to achieve the express advantages, as noted by Lonial et al, which would facilitate the search for hormone agonists and antagonists by the development of a fast and effective in vitro screening system.

13. Claims 49, and 55-56 are rejected under 35 U.S.C. 103 (a) over Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999) in view of Comoglio et al. (U.S. Patent 6,030,949) (February 29, 2000) further in view of Cubicciotti (U.S. Patent 6,287,765 B1) (September 11, 2001).

Lonial et al teach a method of claims 29-33, 46, 53 and 67 as described above.

Art Unit: 1634

Lonial et al do not teach a method, wherein cell is Neuro2a.

Comoglio et al. teach a method, wherein cell is Neuro2a (Examples 2 and 3).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute a method, wherein cell is Neuro2a of Comoglio et al in the method of Lonial et al, since Comoglio et al states, "The invention refers to transduced cells for use in the therapy of the above mentioned pathologies (Column 2, lines 6-8)". Moreover, Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the development of a fast and effective in vitro screening system (Column 2, lines 29-31)". By employing scientific reasoning, an ordinary practitioner would have been motivated to combine and substitute the method wherein glycoprotein is expressed in cells and wherein comparison of the gene expression patterns are made by comparing bands obtained by subjecting a gene group contained in each of gene expression patterns to electrophoretic separation of Gillies et al in the method of Lonial et al. in order to improve the process for detecting an endocrine disrupting action of a test substance and in order to achieve the express advantages, as noted by Comoglio et al, of an invention which refers to transduced cells for use in the therapy of certain neurodegenerative pathologies and also in order to achieve the express advantages, as noted by Lonial et al, which would facilitate the search for hormone agonists and antagonists by the development of a fast and effective in vitro screening system.

Art Unit: 1634

14. Claim 64 is rejected under 35 U.S.C. 103 (a) over Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999) in view of Cubicciotti (U.S. Patent 6,287,765 B1) (September 11, 2001).

Lonial et al teach a method of claims 29-33, 46, 53 and 67 as described above.

Lonial et al. do not teach a method, wherein endocrine hormone is triiodothyronine.

Cubicciotti teaches a method, wherein endocrine hormone is triiodothyronine (Column 182, lines 18-46).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute a method, wherein endocrine hormone is triiodothyronine of Cubicciotti in the method of Lonial et al. in view of Comoglio et al., since Cubicciotti states, "Examples of analytes for which such a complex is useful include, but are not limited to, hormones such as thyroxine and triiodothyronine (Column 182, lines 28-30)".

Moreover, Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the development of a fast and effective in vitro screening system (Column 2, lines 29-31)". By employing scientific reasoning, an ordinary practitioner would have been motivated to combine and substitute the method wherein endocrine hormone is triiodothyronine of Cubicciotti in the method of Lonial et al. in view of Comoglio et al. in order to improve the process for detecting an endocrine disrupting action of a test substance and in order to achieve the express advantages, as noted by Cubicciotti, of triiodothyronine which refers to examples of equivalent useful analyte complex and also in order to achieve the express

Art Unit: 1634

advantages, as noted by Lonial et al, which would facilitate the search for hormone agonists and antagonists by the development of a fast and effective in vitro screening system.

15. Claims 47 and 51 are rejected under 35 U.S.C. 103 (a) over Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999) in view of Makari (U.S. Patent 4,752,471).

Lonial et al teach a method of claims 29-33, 46, 53 and 67 as described above.

Lonial et al. does not teach a method, wherein protein is recovered from the glycoprotein by cutting off the polysaccharide chain and the cell is a cancer cell.

Makari teaches a method, wherein protein is recovered from the glycoprotein by cutting off the polysaccharide chain and the cell is a cancer cell. (Claim 5 and Column 1, lines 28-30).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute the method, wherein protein is recovered from the glycoprotein by cutting off the polysaccharide chain. of Makari in the method of Lonial et al, since Makari states, "The present invention relates to cancer detection preparations, their administrations and their methods of manufacture (Column 1, lines 28-30)." Moreover, Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the development of a fast and effective in vitro screening system (Column 2, lines 29-31)". By employing scientific reasoning, an ordinary practitioner would have been motivated to combine and substitute the method wherein protein is recovered from the glycoprotein by cutting off the polysaccharide chain. of Makari in the method of Lonial et al. in order to improve the process for detecting an endocrine disrupting action of a test substance and

Art Unit: 1634

in order to achieve the express advantages, as noted by Makari, of an invention which relates to cancer detection preparations, their administrations and their methods of manufacture and also in order to achieve the express advantages, as noted by Lonial et al, which would facilitate the search for hormone agonists and antagonists by the development of a fast and effective in vitro screening system.

16. Claims 59-60 are rejected under 35 U.S.C. 103 (a) over Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999) in view of Soto et al. (U.S. Patent 5,135,849) (August 4, 1992).

Lonial et al teach a method of claims 29-33, 46, 53 and 67 as described above.

Lonial et al. do not teach a method, wherein the endocrine hormone is selected from a male hormones androgen, testosterone, or androsterone.

Soto et al. teach a method, wherein the endocrine hormone is selected from a male hormone.(Abstract and Claims 1-12, and Column 11, line 53 to Column 28, line 13).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute the method, wherein the endocrine hormone is selected from a male hormone of Soto et al. in the method of Lonial et al., since Soto et al. states, "The methodology is rapid, reproducible, and accurate, and provides the major advantage of being able to test large numbers of unevaluated substances for their androgen agonistic and/or antagonistic properties as primary properties or secondary side-effects (Abstract, last sentence)." Moreover, Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the development of a fast and effective in vitro

Art Unit: 1634

screening system (Column 2, lines 29-31)". By employing scientific reasoning, an ordinary practitioner would have been motivated to combine and substitute the method, wherein the endocrine hormone is selected from a male hormone of Soto et al. in the method of Lonial et al. in order to improve the process for detecting an endocrine disrupting action of a test substance and in order to achieve the express advantages, as noted by Soto et al., of an invention which is rapid, reproducible, and accurate, and provides the major advantage of being able to test large numbers of unevaluated substances for their androgen agonistic and/or antagonistic properties as primary properties or secondary side-effects.

17. Claims 48, 50, and 52 are rejected under 35 U.S.C. 103 (a) over Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999) in view of Koretzky et al. (U.S. Patent 6,194,633 B1) (February 27, 2001).

Lonial et al teach a method of claims 29-33, 46, 53 and 67 as described above.

Lonial et al. do not teach a method, wherein the cell is a germ cell and normal, nonhuman cell.

Koretzky et al. teach a method, wherein the cell is a germ cell and normal, nonhuman cell.(Abstract and Column 2, lines 23-67).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute the method, wherein the cell is a germ cell and normal, nonhuman cell. of Koretzky et al. in the method of Lonial et al., since Koretzky et al. states, "The configuration of the targeting vector allows for use of the "positive/negative"

Art Unit: 1634

selection technique for selecting homologous recombinants (Column 7, lines 59-61)." Moreover, Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the development of a fast and effective in vitro screening system (Column 2, lines 29-31)". By employing scientific reasoning, an ordinary practitioner would have been motivated to combine and substitute the method, wherein the cell is a germ cell and normal, nonhuman cell. of Koretzky et al. in the method of Lonial et al. in order to improve the process for detecting an endocrine disrupting action of a test substance and in order to achieve the express advantages, as noted by Koretzky et al., of an invention which allows for use of the "positive/negative" selection technique for selecting homologous recombinants.

18. Claims 57-58 are rejected under 35 U.S.C. 103 (a) over Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999) in view of Firestone et al. (U.S. Patent 6,150,395) (November 1, 2000).

Lonial et al teach a method of claims 29-33, 46, 53 and 67 as described above.

Lonial et al. do not teach a method, wherein the endocrine hormone is a female hormone estrogen.

Firestone et al. teach a method, wherein the endocrine hormone is a female hormone estrogen.(Column 2, lines 49-67).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute the method, wherein the endocrine hormone is a female hormone estrogen. of Firestone et al. in the method of Lonial et al., since Firestone et al.

Art Unit: 1634

states, "The invention provides methods and compositions related to novel bioactive compositions. The compositions find particular use as agents for inhibiting cell growth (Column 3, lines 25-27)." Moreover, Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the development of a fast and effective in vitro screening system (Column 2, lines 29-31)". By employing scientific reasoning, an ordinary practitioner would have been motivated to combine and substitute the method, wherein the endocrine hormone is a female hormone estrogen, of Firestone et al. in the method of Lonial et al., in order to improve the process for detecting an endocrine disrupting action of a test substance and in order to achieve the express advantages, as noted by Firestone et al., of an invention which provides methods and compositions related to novel bioactive compositions. The compositions find particular use as agents for inhibiting cell growth.

19. Claims 61-63 are rejected under 35 U.S.C. 103 (a) over Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999) in view of Mascarenhas (U.S. Patent 6,518,238 B1) (February 11, 2003).

Lonial et al teach a method of claims 29-33, 46, 53 and 67 as described above. Lonial et al. do not teach a method, wherein the endocrine hormone is selected from a cortisol, an adrenal cortex hormone and amino acid derivative hormone.

Mascarenhas teaches a method, wherein the endocrine hormone is selected from a cortisol, an adrenal cortex hormone and amino acid derivative hormone.(Column 1, lines 23-53 and Column 2, lines 55-67).

Art Unit: 1634

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute the method, wherein the endocrine hormone is selected from a cortisol, an adrenal cortex hormone and amino acid derivative hormone of Mascarenhas in the method of Lonial et al., since Mascarenhas states, "The invention relates generally to the field of treating psychological and metabolic disorders (Column 1, lines 16-17)." Moreover, Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the development of a fast and effective in vitro screening system (Column 2, lines 29-31)". By employing scientific reasoning, an ordinary practitioner would have been motivated to combine and substitute the method, wherein the endocrine hormone is selected from a cortisol, an adrenal cortex hormone and amino acid derivative hormone of Mascarenhas in the method of Lonial et al. in order to improve the process for detecting an endocrine disrupting action of a test substance and in order to achieve the express advantages, as noted by Mascarenhas, of an invention which relates generally to the field of treating psychological and metabolic disorders.

Response to Amendment

20. In response to amendment, 112 (first and second paragraph) rejections has been included. However, all previous 102(e) and 103(a) rejections have been properly maintained. Four new 103(a) rejection have been included.

Art Unit: 1634

Response to Arguments

21. Applicant's arguments and declaration filed on August 15, 2002 have been fully considered but they are not persuasive.

Applicant argues to withdraw 102(e) rejection in view of the fact that Lonial reference does not teach the detection of endocrine disrupting action of a test substance. This argument is not persuasive. In response to applicant's arguments, the recitation of detection of endocrine disrupting action of a test substance has not been given patentable weight because the recitation occurs in the preamble. A preamble is generally not accorded any patentable weight where it merely recites the purpose of a process or the intended use of a structure, and where the body of the claim does not depend on the preamble for completeness but, instead, the process steps or structural limitations are able to stand alone. See *In re Hirao*, 535 F.2d 67, 190 USPQ 15 (CCPA 1976) and *Kropa v. Robie*, 187 F.2d 150, 152, 88 USPQ 478, 481 (CCPA 1951). Applicant also argues that Lonial does not teach culturing a cell sensitive to an endocrine hormone in the presence of the endocrine hormone and test substance and comparing the gene expression patterns of cells exposed to the test substance and the cells not exposed to the test substance. This argument is not persuasive. Lonial clearly teaches culturing a cell sensitive to an endocrine hormone in the presence of the endocrine hormone and test substance and comparing the gene expression patterns of cells exposed to the test substance and the cells not exposed to the test substance (Claim 12 and column 10, line 65 to column 12, line 16). Applicant also argues that method of Lonial would be ineffective, if the cell lines which express growth hormone reporter

Art Unit: 1634

gene were grown in the presence of growth hormone, as the level of secreted growth hormone protein from the reporter gene could not be accurately measured. This argument is not persuasive. Any ordinary practitioner can add any measured and known amount of growth hormone in the cell culture medium and measure the total amount of growth hormone in the culture after certain period of time. If the known amount of growth hormone is subtracted from the total amount, the level of secreted growth hormone protein from the reporter gene could be accurately measured.

In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Applicant also argues that there is no motivation to combine the references. This argument is not persuasive, especially in the presence pf strong motivation provided by Pearson et al since Pearson et al. states, "Amplification of RNA and DNA targets is often desirable for diagnostic application of amplification technologies, as this gives the greatest number of amplifiable targets per sample. , and as a result, the greatest diagnostic sensitivity. Amplification of RNA targets is also useful for diagnostic monitoring of RNA-related conditions such as certain viremias, up regulation of cancer genes, etc. Amplification of RNA targets is referred to as "reverse transcription amplification", the best known method being reverse transcription PCR.(Column 2, lines 17-26)". The same logic is applicable to other references as well.

Art Unit: 1634

Conclusion

22. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arun Chakrabarti, Ph.D., whose telephone number is (703) 306-5818. The examiner can normally be reached on 7:00 AM-4:30 PM from Monday to Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (703) 308-1119. The fax phone number for this Group is (703) 305-7401.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group analyst Chantae Dessau whose telephone number is (703) 605-1237.

Arun Chakrabarti,

Patent Examiner,

March 25, 2003

Arun K. Chakrabarti
ARUNK. CHAKRABARTI
PATENT EXAMINER